Peyronie Disease: Diagnosis, Acute vs Chronic Phase, and Management Options

Peyronie Disease: Diagnosis, Acute vs Chronic Phase, and Management Options

By gomdori, MD Updated July 6, 2026 ~14 min read Urology

Executive Summary

Peyronie disease is an acquired fibrotic disorder of the tunica albuginea of the penis that produces palpable plaque, painful erections, and abnormal penile curvature. The cumulative prevalence in adult men approaches 9 percent, with peak incidence in the sixth decade, though the true prevalence is likely higher because the disease is widely under-reported. Clinical management depends fundamentally on phase: the acute (inflammatory) phase lasting 6 to 18 months features pain, evolving curvature, and a tender plaque, and is treated with conservative measures aimed at limiting progression — oral pentoxifylline, intralesional verapamil, mechanical traction, and supportive counseling. The chronic (stable) phase begins when curvature stops progressing and pain resolves, opening eligibility for definitive interventions including intralesional collagenase clostridium histolyticum (Xiaflex) for moderate curvature 30 to 90 degrees, and surgical correction (plication, plaque incision with grafting, or penile prosthesis) for greater than 60 degree curvature, complex deformities, or coexisting refractory erectile dysfunction. The cardinal mistake is offering surgery or collagenase during the acute phase before disease has stabilized.

~9%Adult prevalence
55–60Peak age (years)
12–18moAcute phase duration
~13%Spontaneous resolution

Pathophysiology and Risk Factors

Peyronie disease is a localized fibroproliferative disorder of the tunica albuginea — the dense connective tissue layer surrounding the corpora cavernosa. The pathologic process is initiated by microtrauma during intercourse or sleep that produces small tears in the tunica, particularly at the septal attachments where the dorsal and ventral tunica converge. In susceptible individuals, the healing response is dysregulated: instead of producing organized collagen, fibroblasts deposit disorganized type I and type III collagen and elastic fiber bundles that contract over time, producing the characteristic plaque. Calcification develops in advanced disease as the plaque becomes metabolically inactive.

The molecular cascade involves TGF-β1 (transforming growth factor beta), plasminogen activator inhibitor-1 (PAI-1), and reactive oxygen species. TGF-β1 drives myofibroblast differentiation and collagen production; PAI-1 prevents fibrinolysis and allows persistence of the fibrin matrix; reactive oxygen species perpetuate inflammation. Genetic susceptibility appears to involve multiple loci, with strong overlap with other fibrotic disorders.

Recognized associations strengthen the suspicion for Peyronie:

  • Dupuytren contracture — fibrotic palmar fascia disorder; co-occurs in 9 to 39 percent of Peyronie patients and shares the same fibroblast biology
  • Ledderhose disease (plantar fibromatosis) — analogous foot fibrosis, also shares biology
  • Diabetes mellitus — 2 to 4× increased risk; impairs healing of microtrauma
  • Hypogonadism (low testosterone) — associated but causal relationship debated
  • Cardiovascular disease and erectile dysfunction — coexist in approximately 50 percent of Peyronie patients, consistent with shared microvascular pathology
  • Tobacco use — modest increased risk
  • Family history — first-degree relatives have 4-fold increased risk
  • Connective tissue disorders — Marfan, Ehlers-Danlos, scleroderma rare associations

The condition is not infectious, not transmissible, and not caused by sexual practices in any meaningful way. Patients commonly present with significant anxiety about etiology — clear early reassurance that the disease is a healing response to small tears, not a punishment for behavior, helps establish the therapeutic relationship.

Acute vs Chronic Phase Staging

The phase distinction is the most important clinical decision in Peyronie management. It dictates which treatments are appropriate, sets patient expectations about timeline, and defines the natural history.

Table 1. Acute vs chronic phase Peyronie disease
FeatureAcute (inflammatory) phaseChronic (stable) phase
Duration6–18 months from onsetBegins ≥12 months from onset; persistent
Pain with erectionPresent in ~50%Resolved in >90%
CurvatureEvolving, may worsen month to monthStable on serial measurements
Plaque characteristicsTender, palpable, softFirm, often calcified, non-tender
TherapyConservative: traction, oral, intralesional verapamilCollagenase or surgery
Surgical eligibilityContraindicated — curvature will changeEligible if stable ≥6–12 months
Collagenase eligibilityContraindicatedEligible if 30–90° curvature, palpable plaque

The transition from acute to chronic is confirmed by two consecutive office visits 3 months apart with stable curvature measurements and resolved pain. Photographs of the erect penis at each visit provide objective documentation. Patient self-reports of stability are supportive but not sufficient — many patients perceive their curvature as stable after subjective adjustment when serial measurement reveals slow progression.

Why the phase matters: surgical correction performed during the acute phase will need revision when the disease continues to progress, and intralesional collagenase has not been validated in active disease. Equally important, expensive interventions during the acute phase may produce changes that would have occurred with conservative management alone — there is no good way to determine whether observed improvement was treatment effect or natural history.

Diagnosis and Quantification

Peyronie diagnosis is clinical. Physical exam in the flaccid state identifies the plaque as a discrete area of induration along the dorsal, lateral, or (less commonly) ventral aspect of the penile shaft. The dorsal location is most common (~60 percent), reflecting the higher mechanical stress on the dorsal septum during intercourse. Plaques may be solitary or multiple; multiple plaques predict more complex deformity (hourglass, hinge effect).

Curvature Assessment

Quantitative curvature measurement is essential and requires the erect penis. Two approaches:

  1. Patient-provided photographs: the patient photographs the erect penis from three angles (lateral, dorsal, and any prominent angulation) on a flat surface with a measuring tape for scale. Privacy is maintained; goniometric measurement is performed in clinic.
  2. In-office induced erection: intracavernosal injection of alprostadil 5 to 20 mcg or a trimix combination produces a controlled erection for objective measurement and ultrasound. This is the gold standard but requires a dedicated visit.

Curvature is reported in degrees from the long axis (e.g., "45 degrees dorsal curvature"). Severity grading: mild (<30°), moderate (30 to 60°), severe (>60°). Curvature greater than 60 degrees often prevents intercourse and is a strong indication for definitive intervention.

Penile Duplex Ultrasound

Doppler ultrasound after intracavernosal injection serves multiple purposes: visualizes plaque thickness and calcification, assesses cavernosal artery peak systolic velocity (PSV) to identify vascular contributions to erectile dysfunction, and identifies venous leak. PSV less than 25 cm/s indicates arterial insufficiency; end-diastolic velocity (EDV) greater than 5 cm/s indicates venous leak. These findings substantially affect treatment selection — combined Peyronie disease and erectile dysfunction may favor penile prosthesis over plication or grafting.

Erectile Function Quantification

The International Index of Erectile Function (IIEF) short form (5 items) provides a baseline measure of erectile function. Many Peyronie patients have coexistent erectile dysfunction that affects treatment selection. The Peyronie Disease Questionnaire (PDQ) is a validated 15-item instrument assessing pain, symptom bother, and psychological impact — useful as a baseline and outcome measure.

!
Atypical features warranting MRI or biopsyHourglass deformity (circumferential narrowing rather than curvature), rapid plaque growth, plaque enlargement after stable period, palpable mass distinct from plaque, or systemic symptoms should prompt MRI to evaluate for atypical features and very rare differential diagnoses (penile cancer, sarcoidosis, syphilitic gumma, tuberculosis). Biopsy is rare but considered for any suspicious mass.
Peyronie Disease — Procedure Steps Surgical stepper: Peyronie Disease — Procedure Steps Peyronie Disease — Procedure Steps 1 Diagnosis History + exam (palpate plaque); penile US for plaque + ED evaluation; photographs of erection 2 Acute oral Pentoxifylline 400mg PO TID + vitamin E 400 IU BID (limited evidence) 3 Acute traction Penile traction therapy 4-6h/day for 3-6 mo; reduces curvature 4 Intralesional collagenase Collagenase clostridium histolyticum (Xiaflex) for stable curvature 30-90° + palpable plaque 5 Intralesional verapamil Off-label; less evidence than Xiaflex 6 Surgery (chronic) Plication for moderate curvature without ED; plaque incision/excision + grafting for severe; penile
Peyronie Disease — Procedure Steps

Acute Phase Management

The aim of acute-phase therapy is to limit progression of curvature and provide pain relief. No therapy reliably reverses established curvature in the acute phase. Several approaches have evidence-based support and are typically used in combination.

Mechanical Traction Therapy

Penile traction devices apply continuous gentle stretch to the corpora cavernosa for 2 to 8 hours per day. The mechanism is mechanotransduction-driven remodeling of the fibrotic plaque. Multiple randomized trials have shown small reductions in curvature (5 to 15 degrees) and improvement in penile length when used for at least 6 months. Traction is most effective during the acute phase but useful in chronic phase also. Adherence is the limiting factor — daily multi-hour wear is a substantial commitment. Newer devices (RestoreX) have reduced daily wear time to 30 to 90 minutes per day, improving adherence with similar outcomes.

Oral Therapy

Table 2. Oral therapies in Peyronie disease
DrugDoseEvidenceRole
Pentoxifylline400 mg PO TID × 6 monthsSmall RCTs show reduced calcification, modest curvature improvementFirst-line acute phase oral; well-tolerated
Vitamin E400 IU PO BIDMixed; recent meta-analyses negativeOften used for low-cost option but evidence weak
Colchicine0.6 mg PO BIDMixed evidence; GI intolerance limits useAdjunct; rarely first-line
L-arginine, L-carnitineVariableLimited evidenceOften combined with pentoxifylline
PDE5 inhibitors (tadalafil 5 mg daily)Tadalafil 5 mg PO dailyAnimal models suggest antifibrotic effect; clinical data emergingEspecially useful when ED coexists

Intralesional Verapamil

Verapamil 10 mg in 10 mL diluent injected into the plaque every 2 weeks for 12 sessions (6 months) has been used for decades. The evidence is modest but supportive — meta-analyses suggest curvature reduction of approximately 10 degrees. Verapamil is inexpensive and has minimal systemic effects. Use is largely limited to acute phase or as a bridge while waiting for chronic-phase eligibility for collagenase.

Intralesional Interferon

Intralesional interferon alpha-2b 5 million units in 10 mL saline every 2 weeks × 6 doses reduces inflammation and fibrosis. RCT evidence shows modest curvature improvement. Cost and flu-like systemic side effects (fever, myalgias) limit use. Generally reserved for patients who cannot use or have failed verapamil.

What to Avoid in the Acute Phase

  • Surgical reconstruction — disease will continue to progress
  • Intralesional collagenase — not studied or approved in acute phase
  • Aggressive injection regimens — may worsen inflammation
  • Vacuum erection devices alone — limited evidence; can cause additional microtrauma if misused

Clinical Pearl

Use the acute phase wisely. Even though no acute-phase therapy is dramatically effective, the time spent in conservative therapy builds the doctor-patient relationship, allows the patient to develop realistic expectations, and confirms phase transition through serial measurement. Counsel the patient that the goal is to limit progression — not to reverse curvature — until the disease stabilizes.

Common Pitfall

Offering surgery during active disease because the patient is highly symptomatic. The surgical result will need revision when the disease continues to progress. The cardinal rule: stable curvature for at least 6 to 12 months before any surgical intervention. Document stability with serial photographs and measurements.

Chronic Phase: Collagenase and Surgery

Intralesional Collagenase Clostridium Histolyticum (Xiaflex)

Collagenase clostridium histolyticum is the only FDA-approved drug therapy for Peyronie disease. The drug enzymatically cleaves type I and type III collagen, the dominant components of the Peyronie plaque. The IMPRESS phase 3 trials (Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies) demonstrated curvature improvement of approximately 17 degrees (~34 percent reduction from baseline) with collagenase versus 9 degrees with placebo over 4 treatment cycles.

Eligibility criteria: stable disease, palpable plaque, curvature 30 to 90 degrees (excluded if >90 or hourglass deformity), and intact erectile function (or responsive to PDE5 inhibitors). Treatment protocol:

  • One cycle = 2 injections into the plaque separated by 1 to 3 days, followed by penile modeling 1 to 3 days after the second injection
  • Total course = 4 cycles over 6 to 12 months (cycles separated by ~6 weeks)
  • Penile modeling = manual stretching by the clinician (and self-modeling by the patient) to fracture residual plaque after enzymatic disruption

Adverse events include penile bruising and swelling (very common, expected), localized hematoma (5 to 10 percent), pain at injection site, and the most serious — corporal rupture (penile fracture), which occurs in approximately 1 percent of cycles. Patients must abstain from intercourse and self-modeling during specific windows around injection. Cost is substantial (~$30,000 to $50,000 USD for a full course), and insurance coverage is variable.

Surgical Reconstruction

Surgery remains the most effective definitive treatment for Peyronie disease and is the standard for severe curvature, complex deformity, and disease that fails or is ineligible for collagenase. Three procedures address the three major presentations:

Table 3. Surgical options in Peyronie disease
ProcedureBest candidateMechanismTrade-offs
Plication (Nesbit, Yachia, Heineke-Mikulicz)Curvature ≤60°, intact erectile function, adequate lengthShortens convex side to match concave sidePenile shortening 0.5–1.5 cm; high straightening rate; preserves sensation
Plaque incision/excision with graftingCurvature >60°, hourglass deformity, intact erectile functionRemoves/incises plaque, fills defect with graft (autologous, dermal, bovine pericardium)Length-preserving; risk of postoperative ED 10–20%; longer recovery
Inflatable penile prosthesis (IPP) ± modelingCoexisting refractory ED with PeyronieReplaces erectile mechanism; cylinders straighten curvature with manual modeling at implantationDefinitive solution for combined ED+Peyronie; requires lifelong device; infection risk 1–3%

Patient selection considerations: a man with adequate erectile function, mild-moderate curvature, and acceptable preoperative penile length is well served by plication with high satisfaction. A man with severe curvature, hourglass deformity, or substantial preoperative length loss benefits from grafting. A man with combined Peyronie disease and refractory erectile dysfunction is best served by penile prosthesis with intraoperative modeling — this addresses both problems definitively in a single procedure.

Outcomes: plication produces straightening rates greater than 90 percent with high satisfaction. Grafting produces straightening greater than 90 percent but with 10 to 20 percent rate of new or worsened erectile dysfunction. IPP produces excellent satisfaction in patients with combined disease, with greater than 90 percent satisfaction at 1 year.

Erectile Dysfunction Comorbidity, Counseling, and Follow-Up

Coexisting Erectile Dysfunction

Approximately 50 percent of Peyronie patients have coexistent erectile dysfunction. The relationship is bidirectional — Peyronie can produce ED through psychological distress and vascular impingement, and underlying vascular ED contributes to the microtrauma that initiates Peyronie. Evaluation should include IIEF-5 scoring, duplex ultrasound for vascular assessment, and trial of PDE5 inhibitor when erectile complaints are present.

Treatment of coexistent ED is integrated with Peyronie management:

  • Tadalafil 5 mg PO daily — daily PDE5 inhibitor may have antifibrotic benefit and supports erectile function during conservative therapy
  • Sildenafil 50–100 mg PO PRN or Tadalafil 10–20 mg PO PRN — on-demand PDE5i for ED
  • Vacuum erection devices — supplement erectile function and may have modest stretching benefit
  • Penile prosthesis — definitive for refractory ED with concurrent Peyronie correction

Counseling and Psychological Support

Peyronie disease produces significant psychological burden. Depression, anxiety, and relationship distress affect 50 to 75 percent of patients. Open discussion at each visit, validation of the impact, and referral to mental health support when needed are essential components of care. Partner involvement when possible improves adherence and outcomes. Online support groups and patient advocacy organizations (Association of Peyronie’s Disease Advocates) provide community and information.

When to Refer

i
Referral indications to a Peyronie-experienced urologistCurvature ≥60 degrees, complex deformity (hourglass, hinge), eligibility evaluation for collagenase, surgical consideration, coexisting ED requiring prosthesis evaluation, atypical features warranting MRI or biopsy, treatment failure on standard conservative therapy. Many primary care urologists initiate conservative therapy and refer for definitive intervention; sub-specialty referral is appropriate for surgical or device-based management.

Follow-Up

Acute phase: every 3 months with photographs and measurements. Chronic phase pre-treatment: every 3 to 6 months until intervention. Post-collagenase: at 6 weeks, 3 months, and 6 months after the last cycle. Post-surgery: at 2 weeks, 6 weeks, 3 months, 6 months, and annually thereafter. Long-term recurrence after successful surgery is uncommon (<10 percent at 5 years), but new plaques in different locations occur in 5 to 10 percent.

Frequently Asked Questions

What is the difference between acute and chronic phase Peyronie disease?▼
The acute (active or inflammatory) phase typically lasts 6 to 18 months and is characterized by penile pain (especially with erection), evolving curvature, and a tender palpable plaque. The chronic (stable) phase begins when the plaque calcifies, pain resolves, and the curvature stops progressing — typically by 12 to 18 months from symptom onset. The distinction matters because intralesional collagenase and surgical reconstruction are reserved for the stable phase, while conservative measures (oral pentoxifylline, traction therapy, intralesional verapamil) are used during the acute phase to limit progression. Two consecutive office visits 3 months apart with stable curvature confirm transition to chronic phase.
How is Peyronie disease diagnosed?▼
Diagnosis is clinical. Key elements include the history of acquired penile curvature, palpable plaque on exam, and pain with erection during the acute phase. Quantitative assessment uses photography of the erect penis from multiple angles (provided by the patient or generated in clinic with intracavernosal injection of alprostadil) plus a goniometer measurement of the curvature angle. Penile duplex ultrasound after intracavernosal injection visualizes plaque location, calcification, and assesses for vascular insufficiency that contributes to associated erectile dysfunction. MRI is reserved for atypical cases — extensive corporal fibrosis, hourglass deformity, or suspicion of penile malignancy.
Does intralesional collagenase actually work?▼
Collagenase clostridium histolyticum (Xiaflex) is the only FDA-approved drug therapy for Peyronie disease in the chronic phase. The IMPRESS phase 3 trials showed an average curvature improvement of about 17 degrees (~34 percent reduction from baseline) over 4 treatment cycles compared with placebo. Treatment requires 4 cycles, each consisting of 2 injections separated by 1 to 3 days, followed by penile modeling. Total course is 6 to 12 months. Eligibility includes curvature 30 to 90 degrees, palpable plaque, and stable disease. Limitations: cost (substantial), risk of corporal rupture (~1 percent), and modest absolute benefit. Patients with greater than 90-degree curvature, extensive calcified plaque, or hourglass deformity are better served by surgery.
When is surgery indicated for Peyronie disease?▼
Surgery is the definitive treatment for stable-phase Peyronie disease that fails conservative therapy. Indications include curvature greater than 60 degrees that prevents intercourse, complex deformities (hourglass, hinge effect, severe shortening), heavily calcified plaque, and patient preference for one-time correction. Three procedures are used: plication (Nesbit or modified Yachia/Heineke-Mikulicz) for curvatures less than 60 degrees with adequate erectile function, plaque incision/excision with grafting for curvatures greater than 60 degrees with preserved erectile function, and penile prosthesis for combined Peyronie disease and refractory erectile dysfunction. Curvature must be stable for at least 6 to 12 months before any surgery.
Will Peyronie disease resolve on its own?▼
Spontaneous resolution is uncommon — only about 13 percent of patients experience significant curvature improvement without treatment. Approximately 40 to 50 percent remain stable, and 30 to 40 percent worsen during the acute phase. Pain with erection resolves spontaneously in most patients within 12 to 18 months, but the structural curvature persists. Conservative therapy during the acute phase aims to limit progression rather than reverse curvature. Patients should be counseled that watchful waiting is reasonable for mild curvature with intact intercourse function, but progression is more likely than spontaneous improvement.

S7. Practice Insights: Phase Determines Everything in Peyronie Disease

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Peyronie disease runs through an active inflammatory phase and then a stable one, and every treatment choice is right in only one of them: the dominant management failure is phase misclassification — treating an acute-phase patient with surgery before plaque stabilization (recurrence of curvature in the new position), or treating a chronic-phase patient with anti-inflammatory medical management (no effect on stable plaque). In experienced practice, four operational principles guide successful management: rigorous acute vs chronic phase determination at every visit, objective curvature quantification with photographic documentation or in-clinic erection assessment, intralesional collagenase clostridium histolyticum (CCH/Xiaflex) for stable curvature 30-90 degrees, and surgical reconstruction reserved for severe stable disease with informed consent about realistic outcomes including post-surgical length loss.

1. Acute vs Chronic Phase Determination

In practice, every Peyronie patient is staged as acute or chronic phase at the initial visit. Acute phase (typically months 1-12 from symptom onset) is characterized by ongoing pain during erection, palpable inflammatory plaque, progressing curvature on serial measurement. Chronic phase (typically >12 months) shows no pain, stable plaque size, and unchanged curvature angle for at least 3 consecutive months. The clinical importance is that surgical or invasive interventions during acute phase risk recurrence in the new position because the disease is still progressing — definitive intervention requires plaque stabilization. The opposite mistake is treating chronic phase with anti-inflammatory therapies that no longer have a target. clinicians document the phase explicitly at every visit and re-stage if symptoms suggest reactivation.

2. Objective Curvature Quantification

In experienced hands, subjective patient report of curvature is unreliable for both initial assessment and follow-up. Experienced clinicians require objective documentation through one of three methods: patient-submitted photographs of erection (with explicit consent and HIPAA-secure transmission, taken from three angles — dorsal, ventral, lateral), in-clinic intracavernosal injection of vasoactive agent (alprostadil 5-10 mcg) with goniometric measurement at full erection, or duplex ultrasound at maximum erection with measurement. Curvature is reported in degrees from baseline (straight). Curvature less than 30 degrees often does not impact sexual function meaningfully; 30-60 degrees significantly impacts function; greater than 60 degrees often prevents penetration. Hourglass or hinge deformity adds functional impact beyond simple angulation.

3. Collagenase (Xiaflex) for Stable 30-90 Degrees

Intralesional collagenase clostridium histolyticum (CCH/Xiaflex) is FDA-approved for adult men with Peyronie disease with palpable plaque and curvature ≥30 degrees, in stable chronic phase. The treatment course is 4 cycles, each consisting of 2 injections 1-3 days apart followed by modeling/stretching exercises. Total of 8 injections over 24 weeks. In experienced hands, response is typically a 30-40% reduction in curvature angle, which translates to clinically meaningful improvement in sexual function in many patients but does not “cure” the disease. Common complications include local penile bruising and pain; rare but serious complications include corporal rupture (~1%, especially with overly vigorous modeling exercises). Patients must avoid sexual activity for 14 days after each injection cycle. clinicians counsel explicitly about the 30-40% improvement expectation to avoid disappointment from unrealistic expectations.

4. Surgery for Severe Stable Disease

Surgical reconstruction is reserved for severe Peyronie disease with disability from curvature, hourglass deformity, or hinge effect, in stable disease for at least 12 months, often after failed CCH. Two main approaches: plication (Nesbit, Yachia, or 16-dot procedures) for curvatures less than 60-70 degrees in patients without preexisting ED, with expected post-surgical length loss of 0.5-1 cm; plaque incision/excision with grafting (Egydio or similar) for severe curvature or hourglass deformity, with higher rate of postoperative ED and potentially longer length loss but better correction for severe disease. Penile prosthesis with simultaneous manual or surgical straightening is the option for patients with significant concurrent ED. clinicians counsel every surgical candidate about realistic outcomes: residual curvature is common, length loss is essentially universal with plication, and ED can occur post-surgically — particularly important for patients with significant pre-operative ED who may need prosthesis from the outset.

Illustrative Scenario: Failed Acute-Phase Surgery Avoided by Phase Discipline

A middle-aged man presented 4 months after onset of penile pain with erections and progressive dorsal curvature now approximately 55 degrees, with active pain on erection and a palpable inflammatory plaque. He had been referred by an outside urologist who was about to schedule plication surgery. He came for second opinion because his wife felt the timing seemed early.

On the evaluation he was clearly in active acute phase — ongoing pain, palpable tender plaque, curvature that had progressed from 30 to 55 degrees over the prior 8 weeks documented by patient photographs. clinicians counseled against immediate surgery and recommended a 12-month observation/stabilization period with pentoxifylline 400 mg TID and conservative management. Over the next 8 months his pain resolved, plaque became less prominent, and curvature stabilized at 48 degrees (some spontaneous improvement). At 12 months he was clearly chronic phase. The treating clinicians then completed 4 cycles of Xiaflex with reduction of curvature to 30 degrees (achievable for satisfactory intercourse without further surgery). At 2-year follow-up he remained stable, sexually functional, and had avoided surgery entirely.

Takeaway: Acute-phase patients should NOT have definitive surgery. Plaque is still progressing; surgical correction in this window often produces new deformity. The 12-month wait-and-stabilize discipline allows spontaneous improvement in many patients and CCH efficacy in chronic phase. Outside-hospital “let’s just operate now” recommendations need second-opinion review.

Practice Pattern Refinements vs Standard Approach

  • Phase determination at every visit: acute (months 1-12, pain + progression) vs chronic (>12 mo, stable 3+ months). No surgery in acute phase.
  • Objective curvature quantification: photo from 3 angles OR in-clinic injection with goniometric measurement OR duplex US. Document in degrees.
  • CCH (Xiaflex) 4-cycle protocol for stable curvature 30-90°; counsel about 30-40% expected reduction. Modeling exercises with corporal rupture risk (~1%).
  • Surgery for severe stable disease >12 months only: plication if <60-70° without ED; graft if severe/hourglass; prosthesis if concurrent ED. Counsel about realistic length loss and residual curvature.
Peyronie Disease: 4-Pillar Framework Four-panel framework: phase staging, curvature quantification, collagenase, surgery for severe stable disease. Peyronie: 4-Pillar Framework 1. Phase Determination Acute (mo 1-12) Pain w/ erection Inflammatory plaque Progressing curvature NO surgery Chronic (> 12 mo) No pain Stable plaque size Stable 3+ months Intervention OK Re-stage at every visit Treat acute = recurrence in new position Treat chronic w/ AI = no target left 2. Objective Curvature Quantification Methods: Patient photos 3 angles (HIPAA-secure) In-clinic injection + goniometry Duplex US at max erection Clinical significance: < 30°: often no functional impact 30-60°: significant impact > 60°: often prevents penetration 3. CCH/Xiaflex (Stable 30-90°) FDA-approved indication: Palpable plaque + curvature ≥ 30° 4-cycle protocol over 24 weeks 2 injections per cycle + modeling Expected: 30-40% reduction Not a cure; counsel realistic expectations ~1% corporal rupture risk 4. Surgery (Stable > 12 mo, Severe) Plication (< 60-70°, no ED) Expected length loss 0.5-1 cm Plaque incision + graft (severe) Higher postop ED, longer length loss Prosthesis: severe Peyronie + ED Counsel residual curvature + length loss

Leave a Reply

Your email address will not be published. Required fields are marked *